Abstract: Disclosed herein are PEG-DPCA conjugates having multiple hydrophobic DPCA groups at one or both terminal ends of a PEG compound and compositions thereof and methods of using thereof for tissue regeneration and/or cellular repair (e.g., wound healing).

Abstract: Compositions and methods are provided for making and using a cell having expressed on its outer plasma membrane surface an Anchor designed to form a first complex with a selected Linker. The Linker is designed to form a second complex with in a target protein that is not recognized by the Anchor. These cells can be primary cells or immortalized cells, they function as fusion partners to create hybridoma cells. The cells can be designed to bind a secreted targeted protein, e.g., a secreted antibody, to the cell surface via an immune complex formed by the Anchor-Linker and permit the identification of the existence, antigen specificity, and antigen binding affinity, titer, amount, or biological activity of the target protein. In certain embodiments, the Linker is of a species heterologous to the species of the Anchor; and the target protein is of a species heterologous to the Linker and to the Anchor.

Abstract: Compositions and methods for treating a retinopathy or inhibiting pathologic neovascularization in a subject are provided herein. In one embodiment, the method includes ablating or inhibiting IDO-dependent vascularizing cells (IDVCs) in the eye of the subject. Various methods of inhibiting or ablating IDVCs are described, including inhibiting IDO1 and/or integrated response nodes.

Abstract: Fusion proteins, comprising at least one single chain antibody fragment (scFV), and a cancer antigen or marker, or a fragment thereof are provided. The scFV is capable of selectively binding to a cytokine released by chimeric antigen receptor (CAR) expressing cell such as interferon gamma (IFN-?) or tumor necrosis factor alpha (TNF-?). The cancer antigen or marker may comprise the extracellular domain of CD19. Methods for isolating or purifying CAR expressing cells using fusion proteins are provided.

Abstract: The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.

Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.

Abstract: A method for assessing susceptibility to nausea of a patient comprises assessing the GSH recycling dependent antioxidant activity of the patient's blood cells prior to receiving an emetogenic agent, e.g., a cytostatic agent or a surgical anesthetic.

Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.

Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.

Abstract: Compositions and methods for the treatment of an ocular disease or disorder are disclosed.

Abstract: Compositions and methods for the treatment of ocular diseases are disclosed. In accordance with one aspect of the instant invention, methods for treating, inhibiting (e.g., reducing), and/or preventing an ocular disease in a subject are provided. The methods comprise the administration of at least one inhibitor of the induction or activity of tryptophan degradation and/or of the downstream pathways that respond to this process. In a particular embodiment, the methods comprise the administration of an inhibitor of IDO1.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed. Specifically, methods for inhibiting, treating, and/or preventing inflammatory disease in patients in need thereof are provided. The methods comprise the administration of at least one antibody or antibody fragment immunologically specific for bridging integrator I (Bin 1), particularly the Myc binding domain.

Abstract: Compositions and methods for the treatment of ocular diseases are disclosed.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.

Abstract: Anti-RhoB antibodies, compositions comprising the same, and methods for the treatment of autoimmune and inflammatory diseases using the anti-RhoB antibodies are disclosed.

Abstract: Compositions and methods for the treatment of a disease or disorder are disclosed.

Abstract: Compositions and methods for the measuring toxicity, antioxidant capacity, and oxidative stress are provided.

Abstract: Compositions and methods for the treatment of cancer are provided.

Abstract: The invention relates to a method of treating or preventing a condition in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof. The invention further relates to a method of improving a physiological function in a subject, comprising administering to the subject an acceptable composition comprising meglumine or a salt thereof.

Abstract: The nucleotide and amino acid sequences of indoleamine 2,3-dioxygenase-2 (IDO2) and methods of use thereof are provided.